CTPS1
Basic information
Region (hg38): 1:40979300-41012565
Previous symbols: [ "CTPS" ]
Links
Phenotypes
GenCC
Source:
- severe combined immunodeficiency due to CTPS1 deficiency (Strong), mode of inheritance: AR
- severe combined immunodeficiency due to CTPS1 deficiency (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Immunodeficiency 24 | AR | Allergy/Immunology/Infectious; Oncologic | Individuals are susceptible to frequent and severe viral and bacterial infections (as well as sequelae such as EBV-related lymphoma), and and antiinfectious prophylaxis and early and aggressive treatment of infections, as well as awareness of potential oncologic sequelae, may be beneficial; HSCT has been described | Allergy/Immunology/Infectious; Oncologic | 24870241 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (1 variants)
- Severe combined immunodeficiency due to CTPS1 deficiency (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CTPS1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 67 | 73 | ||||
missense | 83 | 85 | ||||
nonsense | 0 | |||||
start loss | 1 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 14 | 12 | 1 | 27 | ||
non coding | 48 | 11 | 60 | |||
Total | 1 | 0 | 91 | 117 | 15 |
Highest pathogenic variant AF is 0.000145
Variants in CTPS1
This is a list of pathogenic ClinVar variants found in the CTPS1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-40983293-G-T | Uncertain significance (Sep 05, 2017) | |||
1-40983371-C-T | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (May 11, 2023) | ||
1-40983388-A-G | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Oct 12, 2021) | ||
1-40983388-A-T | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Apr 01, 2022) | ||
1-40983389-T-C | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Oct 13, 2023) | ||
1-40983405-A-G | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Jan 27, 2022) | ||
1-40983427-A-G | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Oct 13, 2023) | ||
1-40983452-G-A | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Jan 12, 2023) | ||
1-40983462-C-CA | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Apr 27, 2020) | ||
1-40983471-T-G | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (May 21, 2023) | ||
1-40984806-C-G | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Jan 14, 2024) | ||
1-40984808-C-T | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Jul 16, 2023) | ||
1-40984816-T-C | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Aug 16, 2022) | ||
1-40984845-G-A | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Mar 16, 2022) | ||
1-40984852-A-G | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Aug 04, 2023) | ||
1-40984875-A-G | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Nov 16, 2020) | ||
1-40984876-T-C | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Sep 26, 2022) | ||
1-40984887-T-G | not specified | Uncertain significance (Apr 25, 2023) | ||
1-40984895-C-T | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Dec 09, 2020) | ||
1-40984896-G-A | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Jun 08, 2022) | ||
1-40984916-C-G | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Aug 02, 2022) | ||
1-40984941-A-G | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Dec 31, 2019) | ||
1-40984951-C-T | Severe combined immunodeficiency due to CTPS1 deficiency | Likely benign (Nov 02, 2018) | ||
1-40984958-C-T | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Feb 01, 2024) | ||
1-40984959-G-A | Severe combined immunodeficiency due to CTPS1 deficiency | Uncertain significance (Dec 11, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CTPS1 | protein_coding | protein_coding | ENST00000372621 | 17 | 33229 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.993 | 0.00741 | 125712 | 0 | 36 | 125748 | 0.000143 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.69 | 141 | 330 | 0.428 | 0.0000173 | 3859 |
Missense in Polyphen | 32 | 134.59 | 0.23776 | 1568 | ||
Synonymous | 0.395 | 111 | 116 | 0.953 | 0.00000622 | 1118 |
Loss of Function | 4.85 | 5 | 36.7 | 0.136 | 0.00000185 | 443 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000152 | 0.000152 |
Ashkenazi Jewish | 0.000552 | 0.000496 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000924 | 0.0000924 |
European (Non-Finnish) | 0.000220 | 0.000220 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: This enzyme is involved in the de novo synthesis of CTP, a precursor of DNA, RNA and phospholipids. Catalyzes the ATP- dependent amination of UTP to CTP with either L-glutamine or ammonia as a source of nitrogen. This enzyme and its product, CTP, play a crucial role in the proliferation of activated lymphocytes and therefore in immunity. {ECO:0000269|PubMed:16179339, ECO:0000269|PubMed:24870241}.;
- Disease
- DISEASE: Immunodeficiency 24 (IMD24) [MIM:615897]: A life- threatening immunodeficiency, characterized by an impaired capacity of activated T and B cells to proliferate in response to antigen receptor-mediated activation. Patients have early onset of severe chronic viral infections, mostly caused by herpes viruses, including EBV and varicella zooster virus (VZV), and also suffer from recurrent encapsulated bacterial infections, a spectrum of infections typical of a combined deficiency of adaptive immunity. {ECO:0000269|PubMed:24870241}. Note=The disease is caused by mutations affecting the gene represented in this entry. A unique and recessive G to C mutation probably affecting a splice donor site at the junction of intron 17-18 and exon 18 has been identified in all patients. It results in expression of an abnormal transcript lacking exon 18 and a complete loss of the expression of the protein. {ECO:0000269|PubMed:24870241}.;
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);Pyrimidine Metabolism;UMP Synthase Deiciency (Orotic Aciduria);Gemcitabine Action Pathway;MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);Gemcitabine Metabolism Pathway;Beta Ureidopropionase Deficiency;Dihydropyrimidinase Deficiency;Pyrimidine metabolism;UTP and CTP dephosphorylation I;UTP and CTP <i>de novo</i> biosynthesis;Metabolism of nucleotides;Interconversion of nucleotide di- and triphosphates;UTP and CTP dephosphorylation II;Metabolism;superpathway of pyrimidine ribonucleotides <i>de novo</i> biosynthesis;Pyrimidine nucleotides nucleosides metabolism;superpathway of pyrimidine deoxyribonucleotides <i>de novo</i> biosynthesis
(Consensus)
Recessive Scores
- pRec
- 0.262
Intolerance Scores
- loftool
- rvis_EVS
- -0.74
- rvis_percentile_EVS
- 13.94
Haploinsufficiency Scores
- pHI
- 0.612
- hipred
- Y
- hipred_score
- 0.824
- ghis
- 0.662
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- gene_indispensability_score
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ctps
- Phenotype
Gene ontology
- Biological process
- nucleobase-containing compound metabolic process;CTP biosynthetic process;glutamine metabolic process;nucleobase-containing small molecule interconversion;pyrimidine nucleobase biosynthetic process;T cell proliferation;B cell proliferation;response to drug;'de novo' CTP biosynthetic process
- Cellular component
- cytoplasm;cytosol;membrane;cytoophidium
- Molecular function
- CTP synthase activity;ATP binding;identical protein binding